株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオバンキングの世界市場の予測 (2019~2029年)

Biobanking Market Forecasts 2019-2029

発行 Visiongain Ltd 商品コード 229862
出版日 ページ情報 英文 276 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=151.35円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

Back to Top
バイオバンキングの世界市場の予測 (2019~2029年) Biobanking Market Forecasts 2019-2029
出版日: 2019年05月23日 ページ情報: 英文 276 Pages
概要

世界のバイオバンキング市場の市場規模は、2018年時点で22億米ドルに達すると見込まれています。また、2019~2024年のCAGR (複合年間成長率) は6.6%と推計されています。治療目的、特に幹細胞治療関連でのバイオバンクの利用が今後大きくなると期待されています。

当レポートでは、世界のバイオバンキング市場について調査分析し、今後の収益予測に焦点を当てて、データ、動向、機会、ビジネス見通しについて検証して、体系的な情報を提供しています。

第1章 レポート概要

第2章 イントロダクション:バイオバンキングとその活用分野

  • 人体組織バンキング市場の定義と、分析範囲
  • 幹細胞バンキング市場 - 分類方法
  • バイオバンキングとは何か?
  • バイオバンクの主な特性
  • バイオバンキングに含まれるプロセスとは
  • バイオバンクの分類:組織の種類/ボランティアグループ/所有者の分類モデル
    • ボランティアグループ:一般型/特定疾患特化型
    • 所有構造:公共/民間
  • バイオバンキングの標準化:様々な組織による試み
  • バイオバンキングへの資金提供と、財政面での持続性
  • バイオバンキングの指針と基準
  • バイオバンキング関連研究に関する法令と規制
  • バイオバンキングと製薬産業
    • 研究・創薬・薬剤開発におけるバイオバンキング
      • バイオバンキングによる遺伝疫学研究の促進
      • 疾患経路のより良い理解に基づく、新薬の発見
      • 創薬過程におけるバイオマーカーの発見
    • 治療過程におけるバイオバンキング
    • 治験におけるバイオバンキング

第3章 世界のバイオバンキング市場:将来展望

  • 世界のバイオバンキング市場:最新情勢
  • バイオバンキング市場の将来予測:研究用 vs 治療用
  • 世界のバイオバンキング市場:全体的な市場収益額の予測 (今後11年間分)
  • バイオバンクに保管されている標本数:合計で15億個以上
  • 治療用バイオバンキング市場:部門別 - 市場収益額の予測 (総額)
  • 研究用バイオバンキング:大半が非営利組織
    • 市場収益額の予測 (今後11年間分)
    • 促進要因:抑制要因よりも大きな影響力
  • 未来の治療用バイオバンキング - あまりに民間色が強いか?
    • 民営の治療用幹細胞バンキングに関する議論
    • 未来の治療用バイオバンキング:市場収益額の予測 (今後11年間分)
    • 治療用バイオバンキングの促進・抑制要因:将来展望

第4章 研究用バイオバンキング:世界市場の予測

  • 研究用バイオバンキングの分類:組織の種類別
  • 研究用バイオバンキング:将来展望 - 組織の種類別の比較
  • 研究用バイオバンキング、組織の種類別:市場収益額の予測 (総額、今後11年間分)
  • どれだけの標本が、研究用バイオバンクに保管されているのか?
  • 研究用人体組織バンキングの市場:最新情勢
  • 研究用人体組織バンキングの市場:市場収益額の予測 (今後11年間分)
  • 研究用人体組織バンキングの市場:民間/公共部門
    • 民間人体組織バンク:市場収益額の予測
    • 公共人体組織バンク:市場収益額の予測
  • 研究用幹細胞バンキング市場:最新情勢
  • 研究用幹細胞バンキング市場:市場収益額の予測 (今後11年間分)
    • 研究開発 (R&D):iPS細胞への関心の増大
  • その他の研究用生体標本バンキング:最新情勢
  • その他の研究用生体標本バンキング:市場収益額の予測 (今後11年間分)

第5章 未来の治療用幹細胞バンキング:世界市場の予測

  • 治療用幹細胞バンキング:幹細胞の種類別の内訳
  • 治療用幹細胞バンキング、幹細胞の種類別:市場収益額・シェアの比較 (今後11年間分)
  • 治療用幹細胞バンキング、幹細胞の種類別:市場収益額の予測 (総額)
  • 毎年、どれだけの幹細胞がバイオバンクに保存されるのか?
  • 臍帯血バンキング市場:最新情勢
    • 民間/公共臍帯血バンキング
    • 臍帯血バンキング:論争
  • 臍帯血バンキング市場:収益額の予測 (今後11年間分)
  • 成体幹細胞バンキング市場:最新情勢
  • 成体幹細胞バンキング市場:収益額の予測 (今後11年間分)

第6章 世界のバイオバンキング市場:製品別

  • 世界のバイオバンキング市場、製品別:最新情勢
  • 世界のバイオバンキング市場、製品別:将来展望 (今後11年間分)
  • 消耗品市場:将来展望 (今後11年間分)
  • 装置市場:将来展望 (今後11年間分)
  • サービス市場:将来展望 (今後11年間分)

第7章 主要国市場の予測

  • 各地域のバイオバンキングの分布状況
    • 欧州:世界のバイオバンキングネットワーク/インフラを牽引
    • 米国:細分化された市場
    • アジア:急速に勢力を拡大している地域
  • 治療用バイオバンキング:米国が先導
  • 主要国市場:市場収益額の予測 (総額、今後11年間分)
  • 地域別市場シェアの変動見通し
  • 米国のバイオバンキング市場:多様化と拡大
  • 欧州主要国のバイオバンキング市場:バイオバンキング・インフラの整備を主導
    • ドイツ:業界の先導役、74の団体がBBMRIに加盟
    • フランス:民間幹細胞バンキングへの規制が市場を制約
    • イタリア:民間幹細胞バンキングへの制約を、強力な研究ネットワークでカバーできるか?
    • 英国:バイオバンキング・ネットワークのプレゼンスへの制約
    • スペイン:民間/公共臍帯血バンキングに関する議論
    • オランダ:包括的なバイオバンキング・ネットワーク
  • 日本のバイオバンキング市場:政府からの多額の投資が成長を促進
  • BRIC諸国のバイオバンキング市場:成長率の高さと、今後の市場シェア拡大
    • 中国:急速な市場成長の継続
    • インド:民間幹細胞バンキングの牽引役となれるか?
    • ブラジル:新規性は市場成長を促進するか、抑制するか?
    • ロシア:人体組織・遺伝子情報の輸出入禁止 - 将来的な克服は可能か?

第8章 バイオバンキング技術:バイオバンキング関連のシステム・ソフトウェア・消耗品・サービス

  • バイオバンキング関連市場:概要
  • システム技術:完全自動化されたハンドリング
    • 自動液体ハンドリング装置
    • 冷凍サンプル取得 (Frozen Aliquoting):CryoXtractの特許技術
    • 自動DNA単離
  • ストレージ技術:持続可能性、サンプルトラッキングの容易性、付加的セキュリティ機能
    • 乾燥・室温保存:高額でエネルギー消費量も大きい冷凍庫の撤廃
    • 超低温冷凍庫:利用は減少しているのか?
    • 冷凍保存:機械式保存 vs 液体/気相窒素式保存
    • 自動倉庫 (AS/RS):基本的な技術
    • RFIDとタグ技術:バーコードに対する利点
  • バイオバンク用ソフトウェア
    • ラボ情報管理システム (LIMS):昨今の技術進歩にもかからず、アンメットニーズが残存
    • LIMSの機能
  • 消耗品:効果的なサンプリ管理に求められている高品質性
    • サンプル保管・トラッキングの課題への対応
  • バイオバンキングサービス:有償での生体試料の保管・管理・輸送

第9章 バイオバンキング市場の主要企業

  • バイオバンキング企業の様々なビジネスモデル:調達/保管
  • バイオバンキング市場の代表的ベンダー
    • Thermo Fisher Scientific, Inc.
      • 財務実績 (過去4年間分)
      • 戦略展開状況
    • Merck KGaA
    • Qiagen
    • Danaher
  • 民間の研究用バイオバンク
    • Tissue Solutions
    • Asterand Bioscience
    • Biopta
    • BioServe
    • Coriell Institute for Medical Research
  • 代表的な治療用バイオバンク
    • Cord Blood America
    • Cryo-Cell International
    • Cryo-Save
    • China Cord Blood Corp
    • LifebankUSA
    • ViaCord
    • Cord Blood Registry
    • Biogenea Pharmaceuticals
    • StemLife
    • Future Health Biobank
    • Caladrius Biosciences (旧:NeoStem)
    • Precious Cells

第10章 バイオバンキング市場の定性分析

  • 産業動向
    • 研究用のバイオバンク・リソースの需要増大
    • バイオバンキング・ネットワークの整備
      • BBMRI:最も広大なバイオバンク・ネットワーク
    • 仮想バイオバンク:細分化された業界の連携
    • 中間組織としての民間バイオバンク:新たな調査リソース
    • バイオバンキングの自動化:新たな課題
    • LIMS導入の増加
    • グリーン・バンキング:省エネ型バイオバンキング
  • 市場の強み・弱み
  • 市場の機会と脅威
  • 社会的・技術的・経済的・政治的要因 (STEP分析):バイオバンキング市場への影響度
  • ポーターのファイブフォース分析

第11章 結論

  • 世界のバイオバンキング市場の将来展望:急成長の見通し
  • 研究用バイオバンキングの将来展望:保管された標本に対する再評価の動き
  • 治療用バイオバンキングの利用動向見通し:成人向け・幹細胞バンキングの急速な拡大
  • 主要国市場:どの国でも売上高が急速に拡大
  • バイオバンキングの現状と将来性
    • 保管標本の需要増加 - 市場収益額の拡大
    • バイオバンキング・インフラの改良 - 成長促進要因、持続可能性を目指した戦略的計画の必要性
    • 重要な課題も幾つか残るが、市場拡大の機会も大きい

付録

図表

List of Tables

  • Table 2.1 Prominent Population-Based Biobanks, 2018
  • Table 2.2 Prominent Disease-Based Biobanks, 2018
  • Table 2.3 Guidelines and Recommendations for Biobanks, 2018
  • Table 2.4 Laws and Other Regulations for Biobank-Based Research by Country/ Organisation 2018
  • Table 2.5 Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2018
  • Table 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($mn) and Market Share (%), 2018
  • Table 3.2 Biobanking for Research vs. Therapeutics: Revenues ($m), Market Share (%) in 2024 and 2029
  • Table 3.3 Global Biobanking Market: Revenue Forecast ($mn), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 3.4 The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast No. Of Samples (bn), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 3.5 Global Biobanking Market by Application: Revenue Forecasts ($mn), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 3.6 Biobanking Market for Research Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 3.7 Biobanking for Therapeutic Use Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 4.1 The Biobanking for Research Market by Tissue Type: Revenues ($mn) and Market Shares (%), 2018
  • Table 4.2 Biobanking for Research by Tissue Type: A Comparison of Revenues ($mn) and Market Shares (%), 2024 and 2029
  • Table 4.3 Biobanking for Research by Tissue Type: Grouped Forecasts, Revenue ($mn), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 4.4 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 4.5 The Human Tissue Banking Market Forecast: Revenue ($mn), Market Share (%) Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 4.6 The Commercial vs. Public Sector Human Tissue Banking Market: Comparison of Revenues ($mn) and Market Share (%), 2018, 2024 and 2029
  • Table 4.7 Commercial Human Tissue Banking Forecast, Revenue ($mn) Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 4.8 Commercial Human Tissue Banking Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 4.9 Prominent Commercial Human Tissue Banks, 2018
  • Table 4.10 Public Sector Human Tissue Banking Forecast: Revenue ($mn), Market Share (%) Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 4.11 Prominent Public-Funded Human Tissue Banks, 2018
  • Table 4.12 The Stem Cell Banking Market for Research Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 4.13 Prominent Stem Cell Banks Serving the Research Community, 2018
  • Table 4.14 Banking of Other Biologic Specimens for Research Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 4.15 Prominent Biobanks Storing Other Biologic Samples, 2018
  • Table 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Share (%), 2018
  • Table 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($mn) and Market Share (%), 2024 and 2029
  • Table 5.3 Global Therapuetics Market by Stem Cells Type Revenue Forecasts ($mn), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 5.4 The Number of Stem Cell Samples Banked for Therapeutic Use: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 5.5 Prominent Public and Private Cord Blood Banks, 2018
  • Table 5.6 The Umbilical Cord Banking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2018
  • Table 5.7 Prominent Companies in the Adult Stem Cell Banking Industry, 2018
  • Table 5.8 The Adult Stem Cell Banking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 6.1 Global Biobanking Industry by Product: Revenue ($mn) and Market Share (%), 2018
  • Table 6.2 Biobanking Market by Product: 2024 and 2029
  • Table 6.3 Global Biobanking Consumables Market: Revenue Forecast ($mn), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 6.4 Global Biobanking Equipment Market: Revenue Forecast ($mn), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 6.5 Global Biobanking Services Market: Revenue Forecast ($mn), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.1 Breakdown of BBMRI Network Directory Members by Country, 2018
  • Table 7.2 The Leading National Biobanking Markets: Comparison of Revenues ($mn) and Market Shares (%), 2018
  • Table 7.3 Leading National Markets Grouped Forecasts: Revenue ($mn), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.4 Leading National Markets: Comparison of Market Share (%), 2018, 2024 and 2029
  • Table 7.5 US Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.6 The Leading European Markets for Biobanking Grouped Forecasts: Revenue ($mn), Market Share (%) Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.7 Examples of Biobanking Initiatives Funded by the European Commission, 2018
  • Table 7.8 Germany Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.9 French Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.10 Italy Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.11 UK Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.12 Spain Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.13 Prominent Clinical and Population Biobanks in the Netherlands, 2018
  • Table 7.14 The Netherlands Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.15 Japan Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.16 The Biobanking Industry in the BRIC Countries Grouped Forecasts: Revenue ($mn), Market Share (%) Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.17 Chinese Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.18 Indian Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.19 Prominent Research Biobanks in India, 2018
  • Table 7.20 Brazilian Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 7.21 Russian Biobanking Market Forecast: Revenue ($mn), Market Share (%), Annual Growth (%), CAGR (%), 2018 to 2029
  • Table 8.1 Prominent Companies Providing Automated Liquid Handling Technology, 2018
  • Table 8.2 Prominent Companies Providing Room Temperature Storage Solutions, 2018
  • Table 8.3 Prominent Companies Providing Ultra-Low Temperature Freezers (-80°C), 2018
  • Table 8.4 Mechanical Freezing vs. Liquid Nitrogen: Comparison of Advantages and Disadvantages, 2018
  • Table 8.5 Prominent Companies Providing Cryogenic Storage Solutions, 2018
  • Table 8.6 Prominent Providers of Automated Biobanking Systems, 2018
  • Table 8.7 Major Vendors in the LIMS Market, 2018
  • Table 8.8 Prominent Vendors of Consumables for Biobanking, 2018
  • Table 8.9 Prominent Biorepository Service Providers, 2018
  • Table 9.1 Prominent Players in the Biobanking Industry for Research, 2018
  • Table 9.2 Prominent Companies in the Stem Cell Banking Industry for Therapeutic Use, 2018
  • Table 9.3 China Cord Blood Corp: Revenue ($ 000'), Total Units Stored for Subscribers, and No. Of New Subscribers, 2016 to 2018
  • Table 9.4 StemLife: Comparison of Revenue ($m) between 2015 and 2016
  • Table 10.1 Strengths and Weaknesses of the Biobanking Industry, 2018
  • Table 10.2 Opportunities and Threats Facing the Biobanking Industry, 2018 to 2029
  • Table 10.3 Social, Technological, Economic and Political (STEP) Forces Influencing the Biobanking Industry, 2018 to 2029

List of Figures

  • Figure 1.1 Global Biobanking Industry Segmentation Overview, 2018
  • Figure 2.1 Processes Involved in Biobanking, 2018
  • Figure 2.2 The Classification of Biobanks, 2018
  • Figure 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Share (%), 2018
  • Figure 3.2 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2024
  • Figure 3.3 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2029
  • Figure 3.4 Global Biobanking Market: Revenue Forecast ($mn) & Annual Growth (%), 2018 to 2029
  • Figure 3.5 The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast, No. of Samples (bn), 2018 to 2029
  • Figure 3.6 Global Biobanking Market by Application: Revenue Forecasts ($mn), 2018 to 2029
  • Figure 3.7 Biobanking Market for Research: Revenue Forecast ($mn) & Annual Growth (%), 2018 to 2029
  • Figure 3.8 Biobanking for Research: Drivers and Restraints, 2019 to 2029
  • Figure 3.9 Biobanking for Therapeutic Use: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 3.10 Biobanking for Therapeutic Use: Drivers and Restraints, 2019 to 2029
  • Figure 4.1 The Biobanking for Research Market by Tissue Type: Market Share (%), 2018
  • Figure 4.2 Biobanking for Research by Tissue Type: Market Shares (%), 2024
  • Figure 4.3 Biobanking for Research by Tissue Type: Market Shares (%), 2029
  • Figure 4.4 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts ($mn), 2018 to 2029
  • Figure 4.5 Biobanking for Research: Market Drivers and Restraints, 2019 to 2029
  • Figure 4.6 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), 2019 to 2029
  • Figure 4.7 The Human Tissue Banking Market: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 4.8 Human Tissue Banking for Research: Market Drivers and Restraints, 2019 to 2029
  • Figure 4.9 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2018
  • Figure 4.10 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2024
  • Figure 4.11 The Commercial vs. Public Sector Human Tissue Banking Market: Market Share (%), 2029
  • Figure 4.12 The Human Tissue Banking Market by Subsector: Revenue Forecasts ($mn), 2018 to 2029
  • Figure 4.13 Commercial Human Tissue Banking: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 4.14 Public Sector Human Tissue Banking: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 4.15 The Stem Cell Banking Market for Research: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 4.16 Stem Cell Banking for Research: Market Drivers and Restraints, 2019 to 2029
  • Figure 4.17 Banking of Other Biologic Specimens for Research: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 4.18 Biobanking of Other Biologic Specimens for Research: Market Drivers and Restraints, 2019 to 2029
  • Figure 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2018
  • Figure 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2024
  • Figure 5.3 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2029
  • Figure 5.4 Biobanking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts ($mn), 2018 to 2029
  • Figure 5.5 The Number of Stem Cell Samples Banked for Therapeutic Use (m): Forecast 2019 to 2029
  • Figure 5.6 The Stem Cell Banking Market for Future Therapeutic Use: Drivers and Restraints, 2019 to 2029
  • Figure 5.7 The Umbilical Cord Banking Market: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 5.8 The Umbilical Cord Blood Banking Market: Drivers and Restraints, 2019 to 2029
  • Figure 5.9 The Adult Stem Cell Banking Market: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 5.10 The Adult Stem Cell Banking Market: Drivers and Restraints, 2019 to 2029
  • Figure 6.1 Global Biobanking Industry by Product: Market Share (%), 2018
  • Figure 6.2 Biobanking Industry by Product: Market Shares (%), 2024
  • Figure 6.3 Biobanking By Product: Market Shares (%), 2029
  • Figure 6.4 Global Biobanking Consumables Market: Revenue Forecast ($mn) & Annual Growth (%), 2018 to 2029
  • Figure 6.5 Global Biobanking Equipment Market: Revenue Forecast ($mn) & Annual Growth (%), 2018 to 2029
  • Figure 6.6 Global Biobanking Services Market: Revenue Forecast ($mn) & Annual Growth (%), 2018 to 2029
  • Figure 7.1 The Leading National Biobanking Markets: Market Shares (%), 2018
  • Figure 7.2 The Leading National Markets: Grouped Revenue Forecasts ($mn), 2018 to 2029
  • Figure 7.3 The Leading National Markets: Market Share (%), 2024
  • Figure 7.4 The Leading National Markets: Market Share (%), 2029
  • Figure 7.5 US Biobanking Market: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.6 Driving and Restraining Factors of the US Biobanking Market, 2019 to 2029
  • Figure 7.7 The Leading European Markets for Biobanking: Grouped Revenue Forecasts ($mn), 2018 to 2029
  • Figure 7.8 Biobanking in the Leading European Countries: Driving and Restraining Factors, 2019 to 2029
  • Figure 7.9 The German Biobanking Industry: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.10 The French Biobanking Industry: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.11 The Italian Biobanking Industry: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.12 The UK Biobanking Industry: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.13 The Spanish Biobanking Industry: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.14 The Netherlands Biobanking Industry: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.15 The Japanese Biobanking Industry: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.16 Driving and Restraining Factors Influencing the Japanese Biobanking Industry, 2019 to 2029
  • Figure 7.17 The Biobanking Industry in the BRIC Countries: Grouped Revenue Forecasts ($mn), 2018 to 2029
  • Figure 7.18 Driving and Restraining Factors of the Biobanking Industry in the BRIC Countries, 2019 to 2029
  • Figure 7.19 The Chinese Biobanking Industry: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.20 The Indian Biobanking Industry: Revenue ($mn) Forecast, 2019 to 2029
  • Figure 7.21 The Brazilian Biobanking Market: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 7.22 The Russian Biobanking Industry: Revenue Forecast ($mn) & AGR (%), 2018 to 2029
  • Figure 8.1 Structure of the Biobanking Industry: Biobanking-Associated Market, Biobanks and End Users, 2018
  • Figure 8.2 The Basic Function of LIMS
  • Figure 9.1 Biobanking Business Model: Commercial Sourcing of Biological Samples, 2018
  • Figure 9.2 Business Model: Commercial Banking of Biological Samples, 2018
  • Figure 9.3 Thermo Fisher Scientific: Revenue ($bn) 2015-2018
  • Figure 9.4 Merck KGaA: Revenue ($bn) 2015-2018
  • Figure 9.5 Qiagen: Revenue ($bn) 2015-2018
  • Figure 9.6 Danaher: Revenue ($bn) 2015-2018
  • Figure 9.7 China Cord Blood Corp: Revenue ($ ‘000), 2016 to 2018
  • Figure 9.8 StemLife: Comparison of Revenue ($m), 2015 and 2016
  • Figure 10.1 Porters Five Forces Analysis, 2019 to 2029
  • Figure 11.1 The Global Biobanking Market by Application: Market Share (%) 2018-2029
  • Figure 11.2 Biobanking for Research by Sample Type: Comparison of Revenues ($mn), 2018, 2024 and 2029
  • Figure 11.3 Therapeutic Market by Type: Comparison of Revenues ($mn), 2018, 2024 and 2029
  • Figure 11.4 Leading Regional Markets for Biobanking: Comparison of Revenue Share (%), 2018-2029

COMPANIES LISTED:

  • Abbott Laboratories
  • Accelrys
  • Adnexus Therapeutics
  • AIS
  • AKH Biobank
  • AllCells
  • AlloSource
  • American CryoStem
  • American Type Culture Collection (ATCC)
  • Amgen
  • Amsterdam Medical Centre
  • Analytical Biological Services
  • ARUP Laboratories
  • ASPREE Healthy Ageing Biobank
  • AssureImmune
  • Asterand Bioscience
  • AstraZeneca
  • Aurora Biomed
  • Autoscribe Informatics
  • AuxoCell Laboratories
  • AXM Shenyang
  • Bangalore Brain Bank
  • Barts Gynae Tissue Bank
  • Bayer
  • BBMRI
  • Beckman Coulter
  • Beckman Coulter Diagnostics
  • BioCells
  • BioCision
  • BioFortis
  • Biogen Idec
  • Biogenea
  • BioLife Solutions
  • Biomatrica
  • Biopta
  • BioreclamationIVT (BioIVT)
  • BioRep
  • BioRepository Resources
  • BioServe Biotechnologies
  • BioStorage Technologies
  • Biovault Technical
  • BIOVIA
  • BrainNet Europe
  • Bristol-Myers Squibb
  • Brooks Automation
  • Brooks Life Science Systems
  • Broos Automation
  • Caladrius Biosciences
  • California Cryobank Stem Cell Services LLC
  • Cambridge Biomedical Research Centre
  • Cambridge Biosciences
  • Cancer Genetics Inc.
  • Cancer Human Biobank (caHUB)
  • CARTaGENE
  • CCLG Tissue Bank
  • Celgene Cellular Therapeutics
  • Cells4Life
  • Celltex Therapeutics
  • Cellular Dynamics
  • Cepheid
  • Cesca Therapeutics
  • Chernobyl Tissue Bank
  • China Cord Blood Corporation
  • China Kadoorie Biobank
  • China Stem Cells
  • CMD Biobank
  • CONCOR
  • Copper Merger Sub, Inc.
  • CorCell
  • Cord Blood America
  • Cord Blood Registry (CBR)
  • Cordlife
  • CordVida
  • CORE Informatics
  • Coriell Institute for Medical Research
  • Covance
  • Cryo Bio System
  • Cryo-Cell International
  • Cryogenetics
  • CryoLogic
  • Cryopraxis
  • Cryo-Save
  • Cryotherm GmbH
  • Cureline
  • Custom Biogenic Systems
  • Cybrdi
  • Danaher
  • deCODE Genetics
  • Deloitte
  • Diversified Mortgage Investors, Inc.
  • East-West Bio
  • Eli Lilly
  • Estonian Genome Project
  • Fisher BioServices
  • Fox Chase Cancer Centre
  • Future Health Biobank
  • Future Health Biobank
  • GE Healthcare
  • Genentech
  • Genome Quebec Biobank
  • GenVault
  • GlaxoSmithKline (GSK)
  • Golden Meditech Holdings
  • Hamilton Company
  • Hamilton Robotics
  • Hamilton Storage Technologies
  • Harvard Stem Cell Institute
  • Hospital Necker Paris
  • Human Longevity Inc.
  • Hungarian Biobank
  • Huntington Disease Biobank
  • Imperial Tissue Bank
  • Inbiomed
  • Indivumed
  • Infectious Disease Biobank
  • IntegenX
  • International Stem Cell Corporation
  • Kaiser Permanente
  • King's College London Tissue Bank
  • LABVANTAGE
  • Labware
  • LBD Life Sciences Ltd.
  • Leiden Longevity
  • Leiden University Medical Centre
  • LifeBank USA
  • LifeCell Femme
  • LifeGene
  • LifeLines Biobank
  • Malmö Microbiology Biobank
  • MatriCal Bioscience
  • Merck KGaA
  • Mitochondrial Disease Biobank
  • Mitronic
  • Merck Sharp & Dohme (MSD)
  • Nanjing Xinjiekou Department Store Co.
  • Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center
  • NeoStem
  • NESDA
  • Netherlands Twin Registry
  • NHS Blood and Transplant Cord Blood Bank
  • Novare Biologistics
  • Novartis
  • Ocimum Biosolutions
  • OriGene
  • Pacific BioStorage
  • PALGA
  • Panasonic Biomedical
  • Parelsnoer
  • Patheon N.V.
  • PerkinElmer
  • Pfizer
  • Pharma Cells
  • Pharmacells Group
  • Pharmagene
  • Popgen
  • Pop-Gen National Cohort
  • Precious Cells Biobank
  • Precision Bioservices
  • PrecisionMed
  • PREVEND
  • Progenicyte
  • Progenitor Cell Therapy (PCT)
  • ProMedDx
  • ProteoGenex
  • Qiagen
  • ReproCELL Group Company
  • Riken BRC Cell Bank
  • Roche
  • Sanofi
  • Sapien Biosciences
  • Sartorius Stedim Biotech
  • Scéil
  • Seattle Genetics
  • SeqWright Genomic Services
  • Singapore Cord Blood Bank
  • Smart Cells
  • Stanford Tissue Bank
  • StarLIMS
  • Steelgate
  • Stellacure
  • STEMCELL Technologies Inc.
  • StemCyte
  • Stemgent
  • StemLife
  • StemSave
  • Swedish Institute for Infectious Disease Control Biobank
  • System Biosciences
  • TAP Biosystems
  • Tata Memorial Hospital Tissue Bank
  • TCG Life Sciences Tissue Bank
  • Tecan
  • The Cambridge Brain Bank
  • The Guangzhou Biobank
  • The National Cancer Tissue Bank
  • Indian Institute of Technology
  • Thermo Fisher Scientific
  • Thermo Scientific
  • ThermoGenesis
  • Tissue Solutions
  • Titan Pharmaceuticals
  • Totipotent
  • TTP Labtech
  • UCL Biobank
  • UK Biobank
  • UK ME-CFS Biobank
  • UK Multiple Sclerosis Tissue Bank
  • UK Parkinson's Disease Tissue Bank
  • UK Stem Cell Bank
  • US Biomax
  • ViaCord
  • VidaPlus
  • Wisconsin International Stem Cell (WiCell) Bank

List of Organizations Mentioned in the Report:

  • American Association of Tissue Banks
  • Australasian Biospecimen Network (ABN)
  • Bavarian Red Cross (BRK)
  • Biobank Ireland Trust
  • Centro Nazionale per le Risorse Biologiche (CNRB)
  • Coriell Institute for Medical Research
  • European Association for Predictive, Preventative & Personalised Medicine (EPMA)
  • European Health Risk Monitoring (EHRM)
  • Food and Drug Administration (FDA)
  • Harvard University
  • INSERM
  • Instituto de Salud Carlos III
  • International Agency for Research on Cancer (IARC)
  • International Air Transport Association (IATA)
  • International Society for Biological and Environmental Repositories (ISBER)
  • National Cancer Institute (NCI)
  • National Genome Research Network (NGFN)
  • National Institutes of General Medical Sciences
  • Northeastern University
  • Office of Biorepositories and Biospecimen Research (OBBR)
  • RAND
  • Russian Society for Biobanking and Biopreservation (RSBB)
  • Sechenov First Moscow Medical University (SFMMU)
  • Singapore Biobank (SBB)
  • Singapore Tissue Network (STN)
  • Spanish Ministry of Science and Innovation (MICINN)
  • Spanish National Biobank Network
  • The Organisation for Economic Co-operation and Development (OECD)
  • UK Biobank
  • University of Manchester
  • University of Tuebingen
  • US Department of Transportation (DOT)
  • World Health Organization (WHO)
目次
Product Code: PHA0422

In 2018, biobanking for research purposes was estimated at $2.2bn. The overall biobanking market is estimated to grow at a CAGR of 6.6% in the first half of the forecast period. The use of biobanks for therapeutic applications is also increasing, such as in the stem cell banking sector.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 276-page report you will receive 77 tables and 84 figures - all unavailable elsewhere.

The 276-page report provides clear detailed insight into the biobanking market. Discover the key drivers and challenges affecting the market.

Report Scope

Number of samples banked, revenues and growth forecasts from 2019 to 2029 for the global biobanking market

Number of samples banked, revenues and growth forecasts from 2019 to 2029 for the global biobanking market by application:

  • Biobanking for research
  • Biobanking for therapeutic use

Number of samples banked, revenues and growth forecasts from 2019 to 2029 for the research segment:

  • Human tissues: Commercial, Public Sector
  • Stem cells
  • Other applications

Number of samples banked, revenues and growth forecasts from 2019 to 2029 for the therapeutic applications segment:

  • Umbilical cord stem cell banking
  • Adult stem cell banking

Revenues and growth forecasts from 2019 to 2029 for the biobanking market by product:

  • Consumables
  • Equipment: Freezers & Refrigerators, Cryogenic Storage Systems, Incubators & Centrifuges, Thawing Equipment, Temperature Control Systems, Alarms & Monitoring Systems
  • Services

Revenue and growth forecasts from 2019 to 2029 for the global biobanking market by regional and national market:

  • The US and Japan
  • Leading EU countries - Germany, France, the UK, Italy, Spain and the Netherlands
  • The BRIC countries - Brazil, Russia, India and China
  • Discussion and profiles of the leading players in the biobanking industry. This report also provides a list of leading companies for each of the biobanking submarket.
  • Provides and overview of technology used by biobanks. This includes systems, software, consumables and services. Prominent companies providing services are also discussed.
  • Qualitative analyses of the biobanking industry, including industry trends, drivers and restrains, a SWOT analysis, a STEP analysis and Porter's Five Forces analysis of the biobanking market.

Key Questions Answered by this Report:

  • How is the biobanking market evolving?
  • What is driving and restraining biobanking market dynamics?
  • How will each biobanking submarket segment grow over the forecast period and how much revenues will these submarkets account for in 2029?
  • How will market shares of each biobanking submarket develop from 2018-2029?
  • Which biobanking submarket will be the main driver of the overall market from 2018-2029?
  • How will market shares of the national markets change by 2029 and which nation will lead the market in 2029?
  • Who are the leading players?
  • How will the sector evolve as alliances form during the period between 2018 and 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the biobanking market. You find data, trends and predictions.

Buy our report today Biobanking Market Forecasts 2019-2029: Research, Therapeutic, Human Tissue, Stem Cells, Commercial Sector, Public Sector, Umbilical Cord Banking, Adult Stem Cell Banking, Consumables, Equipment, Services, Freezers & Refrigerators, Cryogenic Storage Systems, Incubators & Centrifuges, Thawing Equipment, Temperature Control Systems, Alarms & Monitoring Systems’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Biobanking for Therapeutics: World Market Review 2018 and Global Segmentation
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to Biobanking and its Applications

  • 2.1 Defining the Human Tissue Banking Market for the Scope of this Report
  • 2.2 The Stem Cell Banking Market - Our Breakdown
  • 2.3 What is Biobanking?
  • 2.4 Main Features of Biobanks
  • 2.5 What Processes are Involved in Biobanking?
  • 2.6 Classification of Biobanks: Tissue Type, Volunteer Group and Ownership Classification Models
  • 2.6.1 Volunteer Group: General vs. Disease Population
  • 2.6.2 Ownership Structure: Public vs. Private
  • 2.7 Harmonization of Bio Banking and Initiatives Taken by Various Organizations
  • 2.8 Biobank Funding and Financial Sustainability
  • 2.9 The Guidelines and Standards for Biobanking
  • 2.10 Laws and Regulations for Biobank-Based Research
    • 2.10.1 HIPAA Amendments
  • 2.11 Biobanking and the Pharmaceutical Industry
    • 2.11.1 Biobanking in Research, Drug Discovery and Development
      • 2.11.1.1 Biobanking - Facilitates Genetic Epidemiology Studies
      • 2.11.1.2 Novel Drug Discovery through Better Understanding of Disease Pathways
      • 2.11.1.3 Biomarker Discovery in Drug Development
    • 2.11.2 Biobanking for Therapeutic Purposes
    • 2.11.3 Biobanking in Clinical Trials

3. Global Biobanking Market 2019 to 2029

  • 3.1 The World Biobanking Market in 2018
  • 3.2 Biobanking for Therapeutics: Research vs. Therapeutics in 2024 and 2029
  • 3.3 World Biobanking Market: Overarching Revenue Forecast 2019 to 2029
  • 3.4 Biobanks Stored More Than 1.5 Billion Specimens in 2018
  • 3.5 The Biobanking for Therapeutics Market by Sector: Grouped Revenue Forecasts 2019 to 2029
  • 3.6 Biobanking for Research: Mostly Non-Profit
    • 3.6.1 Biobanking for Research: Revenue Forecast 2019 to 2029
    • 3.6.2 Driving Forces: Outweighs Restraints on the Biobanking Industry for Research
  • 3.7 Biobanking for Future Therapeutic Use: Is It Too Commercial?
    • 3.7.1 Arguments against Commercial Stem Cell Banking for Therapeutic Uses
    • 3.7.2 Biobanking for Future Therapeutic Use: Revenue Forecast 2019 to 2029
    • 3.7.3 Driving and Restraining Forces Influencing the Biobanking Market for Therapeutic Applications, 2019 to 2029

4. Biobanking for Research Purposes: World Market 2019 to 2029

  • 4.1 Breakdown of Biobanking for Research Market by Tissue Type, 2018
  • 4.2 Biobanking for Research in 2024 and 2029: Comparison by Tissue Type
  • 4.3 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts 2019 to 2029
  • 4.4 How Many Specimens are Biobanked for Research?
  • 4.5 The Human Tissue Banking Market for Research in 2018
  • 4.6 The Human Tissue Banking Market for Research: Revenue Forecast 2019 to 2029
  • 4.7 The Human Tissue Banking Market: Commercial vs. Public Sector
    • 4.7.1 Commercial Human Tissue Banks: Revenue Forecast 2019 to 2029
    • 4.7.2 Public Sector Human Tissue Banks: Revenue Forecast 2019 to 2029
  • 4.8 The Stem Cell Banking Market for Research in 2018
  • 4.9 The Stem Cell Banking Market for Research: Revenue Forecast 2019 to 2029
    • 4.9.1 R&D- Growing Interest Towards iPSCs
  • 4.10 Banking of Other Biologics Specimens for Research in 2018
  • 4.11 Banking of Other Biologic Specimens for Research: Revenue Forecast 2019 to 2029

5. Stem Cell Banking for Future Therapeutic Use: World Market 2019 to 2029

  • 5.1 Stem Cell Banking for Therapeutic Use in 2018: A Breakdown by Stem Cell Type
  • 5.2 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenue and Market Share, 2024 and 2029
  • 5.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts
  • 5.4 How Many Stem Cells Are Biobanked Each Year?
  • 5.5 The Umbilical Cord Blood Banking Market in 2018
    • 5.5.1 Private vs. Public Cord Blood Banking
    • 5.5.2 Umbilical Cord Blood Banking: The Controversies
  • 5.6 The Umbilical Cord Blood Banking Market: Revenue Forecast 2019 to 2029
  • 5.7 The Adult Stem Cell Banking Market in 2018
  • 5.8 The Adult Stem Cell Banking Market: Revenue Forecast 2019 to 2029

6. Global Biobanking Market by Product 2019 to 2029

  • 6.1 The World Biobanking Market by Product in 2018
  • 6.2 Biobanking Market by Product: 2024 and 2029
  • 6.3 Consumables Market: Overarching Revenue Forecast 2019 to 2029
  • 6.4 Equipment Market: Overarching Revenue Forecast 2019 to 2029
  • 6.5 Services Market: Overarching Revenue Forecast 2019 to 2029

7. Leading National Markets 2019 to 2029

  • 7.1 The Geographical Footprint of Biobanking
    • 7.1.1 Biobanking in Europe: Leading the World with Biobanking Networks and Infrastructure
    • 7.1.2 Biobanks in the US: A Fragmented Picture
    • 7.1.3 Biobanking in Asia: A Region Fast Gaining Prominence
  • 7.2 Biobanking for Therapeutics: The US Led the Way in 2018
  • 7.3 The Leading National Markets: Grouped Revenue Forecasts 2019 to 2029
  • 7.4 How Will Regional Market Shares Change to 2029?
  • 7.5 The US Biobanking Market 2019 to 2029: Diversifying and Expanding
  • 7.6 The Top European Biobanking Markets 2019 to 2029: Leading the Way in Biobanking Infrastructure
    • 7.6.1 Germany: An Advanced Industry with 74 Biobanks Associated with the BBMRI
    • 7.6.2 France: Restrictions on Private Stem Cell Banking Limit the Market
    • 7.6.3 Italy: Is the Limited Private Stem Cell Banking Market Off-Set by Strong Biobanking Networks for Research?
    • 7.6.4 UK: Limited Presence of Biobanking Networks
    • 7.6.5 Spain: Controversy Between Private and Public Umbilical Cord Blood Banks
    • 7.6.6 The Netherlands is Characterised by Comprehensive Biobanking Networks
  • 7.7 The Japanese Biobanking Market 2019 to 2029: A High Level of Government Investment Drives Growth
  • 7.8 The Biobanking Industry in the BRIC Countries: High Growth and Increasing Market Share between 2019 and 2029
    • 7.8.1 The Chinese Biobanking Market 2019 to 2029: The High Rate of Growth Will Continue
    • 7.8.2 The Indian Biobanking Market 2019 to 2029: Set to Become the Leading Market for Private Stem Cell Banking?
    • 7.8.3 The Brazilian Biobanking Market 2019 to 2029: Will New Regulations Drive or Restrain the Market?
    • 7.8.4 Russia: Ban on the Import and Export of Human Tissue and Genetic Information Restricts the Market, can this be Overcome?

8. Technology for Biobanking: Systems, Software, Consumables, and Services Associated with Biobanking

  • 8.1 The Biobanking-Associated Market: Overview
  • 8.2 Systems Technology: Fully Automated Handling
    • 8.2.1 Automated Liquid Handling Systems
    • 8.2.2 Frozen Aliquoting: Patented Technology from CryoXtract
    • 8.2.3 Automated DNA Isolation
  • 8.3 Storage Technology: Sustainability, Easy Sample Tracking, and Added Security
    • 8.3.1 Dry State, Room Temperature Storage Eliminates the Need for Expensive, Energy-Consuming Freezers
    • 8.3.2 Ultra-Low Temperature Freezers: Is Their Use Declining?
    • 8.3.3 Cryopreservation: Mechanical vs. Liquid/ Vapour Phase Nitrogen
    • 8.3.4 Automated Storage and Retrieval Systems: Essential Technology
    • 8.3.5 RFID and Tagging Technology: Advantages over Barcodes
  • 8.4 Software for Biobanks
    • 8.4.1 Laboratory Information Management System (LIMS): Unmet Needs in the Market Remain, Despite Recent Advances
    • 8.4.2 LIMS Functions
  • 8.5 Consumables: High Quality Required for Effective Sample Management
    • 8.5.1 Addressing Sample Storage and Tracking Issues
  • 8.6 Biobanking Services: Storage, Management and Transport of Biologic Samples for a Fee

9. Leading Companies in the Biobanking Market, 2018

  • 9.1 The Differing Business Models of Biobanking Companies: Sourcing vs. Storing
  • 9.2 Leading Vendors of Biobanking Market 2018
    • 9.2.1 Thermo Fisher Scientific, Inc.
      • 9.2.1.1 Thermo Fisher Scientific: Financials 2015-2018
      • 9.2.1.2 Strategic Developments
    • 9.2.2 Merck KGaA
      • 9.2.2.1 Merck KGaA: Financials 2015-2018
      • 9.2.2.2 Strategic Developments
    • 9.2.3 Qiagen
      • 9.2.3.1 Qiagen: Financials 2015-2018
    • 9.2.4 Danaher
      • 9.2.4.1 Danaher: Financials 2015-2018
      • 9.2.4.2 Strategic Developments
  • 9.3 Commercial Biobanks for Research Purposes in 2018
    • 9.3.1 Tissue Solutions: A Virtual Biobank with a Global Presence
    • 9.3.2 An Overview of the Products and Services Offered by Tissue Solutions
    • 9.3.3 Banked Samples Occur in Many Formats
    • 9.3.4 Prospective Tissue Collection for Hard-to-Find Samples
    • 9.3.5 Fresh Samples from Surgical Resections are in High Demand
    • 9.3.6 Freshly Isolated Human Cells are a Valuable Research Tool
    • 9.3.7 FDA/EMA Panel of Normal Tissues
    • 9.3.8 Strengths, Capabilities and the Future Outlook for Tissue Solutions
    • 9.3.9 Asterand Bioscience is now Part of Stemgent
      • 9.3.9.1 Asterand's Products and Services: XpressBANK, BioSpoke and PhaseZERO
      • 9.3.9.2 The Future Outlook for Asterand
    • 9.3.10 Biopta: Human Tissue Provider Now Acquired by Japanese Company ReproCELL
      • 9.3.10.1 Services from Biopta: A Variety of Lab Services and Fresh Tissue Sample Procurement
      • 9.3.10.2 The First Catalogue of Assays Based on Human Functional Tissues
      • 9.3.10.3 The Future Outlook for Biopta: Fresh Tissue Will Be in Demand
    • 9.3.11 BioServe: One of the World's Largest Commercial Biorepositories
      • 9.3.11.1 BioServe Offers a Comprehensive List of Services: Biobanking, Sourcing and Preclinical Molecular Services
      • 9.3.11.2 The Future Outlook for BioServe
    • 9.3.12 Coriell Institute for Medical Research: Reportedly the Largest Biobank in the World
      • 9.13.2.1 Features of and Recent Developments at Coriell Biobank
      • 9.3.12.2 Future Outlook for the Coriell Biobank
  • 9.4 Prominent Biobanks for Therapeutic Use in 2018
    • 9.4.1 Cord Blood America: Expansion into the Emerging Markets Apparently Stalled, Strategic Alternatives Being Considered
    • 9.4.2 Cryo-Cell International: The First Private Cord Blood Bank in the Market
    • 9.4.3 Cryo-Save's Educational Programme Benefits Company's Growth
    • 9.4.4 China Cord Blood Corp: The Only Cord Blood Bank in China with Multiple Licences Is Under a New Owner
    • 9.4.5 LifebankUSA: Acquisition from Human Longevity Inc Will Potentially Drive Growth
    • 9.4.6 ViaCord: More Blood Units Released for Therapy than Any Other Family Bank
    • 9.4.7 Cord Blood Registry: The World's Largest Newborn Stem Cell Company Will Be Promoted by New Parent Company
    • 9.4.8 Biogenea Pharmaceuticals: A Comprehensive Offering of Stem Cell Banking Services across the Balkan Peninsula
    • 9.4.9 StemLife is Reportedly Facing Challenges due to Government Regulations in Malaysia
    • 9.4.10 Future Health Biobank: A Strong Market Presence Owing to International Operations
    • 9.4.11 Caladrius Biosciences (formerly NeoStem): More Focus on Cell Therapy Than Stem Cell Banking
    • 9.4.12 Precious Cells is Well Positioned to Take Advantage of the Growing Demand in India

10. Qualitative Analysis of the Biobanking Market 2019 to 2029

  • 10.1 Industry Trends
    • 10.1.1 The Growing Demand for Biobank Resources for Research
    • 10.1.2 The Establishment of Biobanking Networks
      • 10.1.2.1 BBMRI: The Most Extensive Biobank Network
    • 10.1.3 Virtual Biobanks: Connecting a Fragmented Industry
    • 10.1.4 Commercial Biobanks as Intermediaries: New Resources for Research
    • 10.1.5 Automated Biobanking Has Become Imperative
    • 10.1.6 Increasing Uptake of LIMS
    • 10.1.7 Green Banking - Becoming More Energy Efficient
  • 10.2 The Strengths and Weaknesses of the Biobanking Market in 2017
    • 10.2.1 HBS are Valuable Resources for R&D
    • 10.2.2 Governmental Support for Biobanking Forms a Strength of that Industry
    • 10.2.3 Development of Potential Novel Stem Cell Therapies has Increased Public Awareness of Stem Cell Banking
    • 10.2.4 The Effect of Big Data on Biobanking
    • 10.2.5 Insufficient Accessible Numbers of High Quality Biospecimens
    • 10.2.6 Biobanks are Fragmented and Uncoordinated
    • 10.2.7 Lack of Standardisation is a Weakness of the Industry
    • 10.2.8 Lack of Public Awareness Limits Number of Donors
    • 10.2.9 Lack of Engagement with Public Health Services Limits the Stem Cell Banking Market
  • 10.3 Opportunities and Threats Facing the Biobanking Market, 2019 to 2029
    • 10.3.1 Increasing Use of Biobanked Specimens in Genome-Wide Association Studies (GWAS)
    • 10.3.2 Increasing Demand for Biobanked Samples for Preclinical Research
    • 10.3.3 Biobanking Networks as a Basis for Personalised Medicine
    • 10.3.4 Options for Adult Stem Cell Banking Mean an Increasing Target Population for Private Stem Cell Banks
    • 10.3.5 Even with Governmental Funding, Biobanks Must Become Self-Sufficient to Thrive Long-Term
    • 10.3.6 Public Concerns over Confidentiality and Security Threaten Availability of Donors
    • 10.3.7 Limitations Surrounding Informed Consent
  • 10.4 Social, Technological, Economic and Political Factors (STEP) Influencing the Biobanking Industry, 2019 to 2029
  • 10.5 Porters Five Forces Analysis, 2019 to 2029
    • 10.5.1 Bargaining Power of Supplier: Low
    • 10.5.2 Bargaining Power of Buyer: Moderate
    • 10.5.3 Competitive Rivalry: High
    • 10.5.4 Threat of New Entrants: Moderate
    • 10.5.5 Threat of Substitutes: Low

11. Conclusion

  • 11.1 World Biobanking Market 2019 to 2029: High Revenue Growth Predicted
  • 11.2 Biobanking for Research 2019 to 2029: The Value of Biobanked Specimens is Increasingly Recognised
  • 11.3 Biobanking for Therapeutic Use 2019 to 2029: Rapid Expansion in Adult Stem Cell Banking
  • 11.4 The Leading National Markets: High Sales Growth Worldwide
  • 11.5 Current and Future Trends in Biobanking
    • 11.5.1 Increasing Demand for Biobanked Samples - Increasing Revenue
    • 11.5.2 Improving Biobanking Infrastructure - Growth Driver and a Need for Strategic Planning for Sustainability
    • 11.5.3 Marked Challenges, but Opportunities for Expansion

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form
Back to Top